期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿托伐他汀钙对高血压患者血脂及超敏C-反应蛋白的影响

下载PDF
导出
摘要 目的:观察阿托伐他汀钙对高血压合并高脂血症及超敏C-反应蛋白的影响。方法:对76例高血压病合并高血脂症患者,在常规降压治疗基础上加服阿托伐他汀钙10mg,1次/d,睡前服用,检测用药前后4周研究对象血脂、超敏C-反应蛋白、血压等因素的变化。结果:高血压病合并高脂血症患者经调脂和降压治疗后,血脂与血压显著下降(P<0.05),超敏C-反应蛋白水平显著下降(P<0.05)。结论:阿托伐他汀钙可明显降低高血压病合并高脂血症患者超敏C-反应蛋白水平,从而可能改善高血压病合并高脂血症患者的炎症状态,减缓动脉粥样硬化的形成。
作者 薛春燕 贺文婷
机构地区 陕西省宁强县医院 西安市第四医院内科
出处 《深圳中西医结合杂志》 2010年第4期246-248,共3页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
关键词 阿托伐他汀钙 高血压病 高脂血症 超敏C-反应蛋白
分类号 R544.1 [医药卫生—心血管疾病] R589.2 [医药卫生—内分泌]
  • 相关文献

参考文献12

  • 1Davidson MH. Clinical significance of statin pleiotroic effects hypotheses versus evidence [J]. Circulation, 2005, 111 (18):2280.
  • 2罗远英,滕日添.他汀类药物防治缺血性卒中和短暂性脑缺血发作研究进展[J].内科,2007,2(6):973-975. 被引量：6
  • 3Sesso B. The patients with high level of serum CRP have a higher risk incidence with EH [J]. JAMA, 2003, 290: 29452-29501.
  • 4Magen E, Mishal J, Paskin J, et al. Resistant arterial hypertension is associated with higher blood levels of complement C3 and Creactive protein [J]. J Clin Hypertens (Greenwich), 2008, 10(9):6772-6831.
  • 5Parissis JT, Korovesis S, Giazitzoglou E, et al. Plasma profiles of Peripheral monocyte related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin- 1 [J]. Int J Cardiol, 2002, 83:13- 21.
  • 6Derhaschnig U, ShehataM, Herkner H, et al. Increased levels of transforming growth factor betal in essential hypertension[J]. Am J Hypertens, 2002, 15:207-211.
  • 7PockleyA G, De FaireU, Kiessling R, et al. Circulating heat shock protein and heat shock protein antibody levels in established hypertension [J]. J Hypertens, 2002, 20:815-820.
  • 8Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductas einhibitor simvastatin activates the protein kinaseAkt and promotes angiogenesis innormocholesterolemic an imals [J]. Nat Med, 2000, 6(9):1004-1010.
  • 9Rikitake Y, Kawashima S, Takeshita S, et al. Antioxidative properties of fluvastatin an HMG-CoA reductase inhibitor contribute to prevention of atherosclerosis in cholesterol fed rabbits [J]. Atherosclerosis, 2001, 154(1)87-96.
  • 10Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in nor mocholesterolemic hypertension via reduced production of reactive oxygen species [J]. Hypertension, 2001, 137(6):1450-1457.

二级参考文献16

  • 1吕瑞娟,张运,陈玉国,孙袆,王文君.他汀类药物治疗ALT升高的急性冠状动脉综合征的可行性研究[J].新医学,2006,37(6):368-369. 被引量：16
  • 2Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes:a randomised placebo-controlled trial[J]. Lancet ,2003,361:2005-2016.
  • 3Sever PS,Dahlof B, Poulter NR,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) : a multicenter randomized controlled trial[J]. Lancet,2003,361:1149-1158.
  • 4Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention[J]. Circulation ,2003,107:363-369.
  • 5Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J]. N Engl J Med,2002,347:1557-1565.
  • 6Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14,719 initially healthy Americau women[J]. Circulation,2003,107:391-397.
  • 7Ridker PM, Rifai N, Pfeffer M, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein[ J]. Circulation, 1999,100:230-235.
  • 8Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation(PRINCE) :a randomized trial and cohort study[J]. JAMA,2001,286:64-70.
  • 9Strandberg TE,Vanhanen H,Tikkanen M J, Association between change in C-reactive protein and serum lipids during statin treatment[J]. Ann Med,2000,32 :579-583.
  • 10van Wissert S, Trip MD, Smilde TJ, et al. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy [J]. Atherosclerosis ,2002,165:361-366.

共引文献41

深圳中西医结合杂志
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部